ASH 2019 | Real world data for axi-cel in lymphoma with secondary CNS involvement
Yi Lin
• 8 Dec 2019
In the ZUMA-1 trial leading to the FDA approval of axicabtagene ciloleucel (axi-cel), patients with prior or active secondary central nervous system (CNS) lymphoma involvement were excluded. However, understanding the outcomes of axi-cel in this setting is important. Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses the results from the US Lymphoma CAR-T Consortium real world experience in patients treated with axi-cel who had a history of secondary CNS involvement or had active CNS disease at time of CAR-T infusion. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
